Acorda Stock Hits New 52-Week Low (ACOR)

NEW YORK ( TheStreet) -- Acorda Therapeutics (Nasdaq: ACOR) hit a new 52-week low Friday as it traded at $21.09 compared with its previous 52-Week low of $21.75. Acorda is changing hands at $21.09 with 78,979 shares traded as of 9:31 a.m. ET. Average volume has been 840,800 shares over the past 30 days. Acorda has a market cap of $906.6 million and is part of the health care sector and drugs industry. Shares are down 14.9% year to date as of the close of trading on Thursday.

Acorda Therapeutics, Inc., a biotechnology company, develops therapies for multiple sclerosis, spinal cord injury, and other nervous system disorders.

TheStreet Ratings rates Acorda as sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and weak operating cash flow. You can view the full Acorda Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Oil Falls Sharply After Saudi Arabia, Russia Suggest Production Cut Easing

Oil Falls Sharply After Saudi Arabia, Russia Suggest Production Cut Easing

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

Netflix Ready to Surpass Disney as America's Most Valuable Media Company

Netflix Ready to Surpass Disney as America's Most Valuable Media Company

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves